



START TREATING YOUR FABRY DISEASE NOW AND

YOU WILL THANK

You

FOR PUTTING
YOUR HEALTH FIRST

AS A FEMALE WITH FABRY, YOU ARE NOT JUST A "CARRIER."
You can suffer from progressive symptoms, including organ damage.
Be your own advocate and **talk to your doctor today.**


Fabrazyme®
agalsidase beta

FIRST FOR FABRY

Sophia and Blanca,
daughter and mother, living with Fabry disease.

INDICATION AND USAGE

Fabrazyme® is used to treat adults and children 2 years of age and older with confirmed Fabry disease.

IMPORTANT SAFETY INFORMATION

WARNING: SEVERE ALLERGIC REACTIONS

Patients treated with enzyme replacement therapies have experienced allergic reactions, including severe or life-threatening reactions (known as anaphylaxis). Anaphylaxis has occurred during the early course and after repeated treatment with enzyme replacement therapy.

Your healthcare professional should initiate Fabrazyme in a healthcare setting with appropriate medical monitoring and support measures. If a severe allergic or anaphylactic reaction occurs, your healthcare professional will immediately stop the infusion and provide appropriate medical treatment. Seek immediate medical care should symptoms occur.



Please see [Important Safety Information](#) and full [Prescribing Information](#), including **Boxed WARNING**





FEMALES WITH FABRY DISEASE

are not JUST “CARRIERS”

WHY DO FEMALES EXPERIENCE A RANGE OF SYMPTOMS WITH FABRY DISEASE?

This happens because of X-chromosome inactivation (described below). Fabry is an **X-linked genetic disease**, which means it’s caused by a **change in a gene** (called the **GLA gene**) located on the **X chromosome**. This altered gene can be passed down by either parent.


HOW FEMALES INHERIT AND PASS DOWN FABRY DISEASE



A person who inherits the altered Fabry gene is unable to produce enough of an enzyme called **alpha-galactosidase A** (pronounced al-fa-ga-lak-toesi-daze a), or **alpha-GAL**. This enzyme is important in the healthy functioning of organs.



Females have two **X chromosomes** in every cell. In a random process before birth, one of the X chromosomes becomes inactivated (turned off). For females with Fabry disease, this **X-inactivation** results in a mix of cells with a working/active *GLA* gene and cells with a non-working/inactive *GLA* gene.



It is this mix of cells with a **working** copy of the *GLA* gene and cells with a **non-working or inactive** copy of the *GLA* gene (also called “**mosaicism**”) that causes the range of symptoms in females with Fabry.



In females with Fabry, certain organs may have more cells with a working/active copy of the *GLA* gene than others. This will allow some cells in the body to produce normal alpha-GAL, which is why **affected females may have more variable symptoms** than affected males.

FEMALE INSIGHT: BECAUSE FEMALES CAN DEVELOP LIFE-THREATENING SYMPTOMS, ALL FEMALES WITH FABRY DISEASE SHOULD BE SEEN REGULARLY BY THEIR DOCTORS.



FEMALES WITH FABRY DISEASE CAN SUFFER FROM *life-altering* SYMPTOMS

FABRY DISEASE MAY IMPACT ORGANS IN FEMALES

Females with Fabry have higher occurrence of serious complications than females in the general population:

End-stage
kidney disease



Brain vessel
damage



Stroke or
ministroke



Thickening of
left heart chamber



In the Fabry Registry, ~70% of females reported having signs and symptoms.*



45% have abdominal pain



43% have nerve pain



39% have diarrhea



39% have protein in their urine

*Data as of January 2007, including 1077 females enrolled in the Fabry Registry, an ongoing international observational program for patients with Fabry disease.

FEMALE INSIGHT: GASTROINTESTINAL (GI) SYMPTOMS AND NEUROPATHIC (NERVE) PAIN COULD BE RED FLAGS SUGGESTING THAT DANGEROUS UNDERLYING ORGAN DAMAGE IS OCCURRING.



ROUTINE MONITORING IS *vital* TO KEEP YOUR ORGAN HEALTH IN CHECK

Females with Fabry disease are at risk for potentially life-threatening problems, so it's important to have regular checkups and map disease progression over time, even if you don't feel sick. This could help you notice if symptoms are progressing and affecting your internal organs such as your kidney or heart.

Organ damage can progress "silently" even if you don't feel sick. Medical assessments are needed to monitor these symptoms, especially since they can affect the kidney, heart, and brain.

Some of the ways Fabry disease can affect you:

Impaired kidney function

- Kidney failure
- Protein in urine

Heart problems

- Chest pain
- Heart disease
- Enlarged heart
- Irregular heartbeat

Strokes and ministrokes

Stomach disorders

- Diarrhea
- Constipation
- Stomach cramping

Skin and nerve conditions

- Reddish or purple spots on skin
- Reduced ability to sweat
- Nerve pain in hands or feet
- Sensitivity to hot and cold temperatures

Additional complications

- Hearing loss or ringing in the ears
- Marble-like pattern in the eyes (corneal whorling)
- Headaches, lightheadedness, vertigo
- Breathing problems

TESTS TO MONITOR FABRY DISEASE

Your doctor can order certain diagnostic tests and labs to measure the function of your kidneys, heart, and brain to understand the effects of Fabry disease on your body. Tests can be performed as often as every 6 months or as infrequently as every 3 years, depending on your age, clinical presentation, and/or other factors. More frequent testing may be needed if you experience new or more severe symptoms, or when you start or change your treatment plan.

Some tests you may need:



Urine and
blood tests



MRI scan



Echocardiogram
(echo), ECG/EKG

MAKE YOUR HEALTH A PRIORITY BY SCHEDULING
ROUTINE ASSESSMENTS WITH YOUR DOCTOR TO
MONITOR ORGAN FUNCTION.



You WILL THANK *You* FOR PUTTING YOUR ORGAN HEALTH FIRST

Treatment guidelines state that enzyme replacement therapy (ERT) like Fabrazyme® should be considered for females with early signs and symptoms of disease progression.

Guidelines are a tool for doctors to consider when making treatment recommendations. If you have questions about the guidelines for Fabry disease, talk to your doctor.



What are **5 key questions** about Fabry you should discuss with your doctor? [Find out here.](#)



FEMALE INSIGHT: FABRY IS PROGRESSIVE, AND ERT SHOULD BE CONSIDERED AT EARLY SIGNS OF DISEASE IN FEMALES.

Ivela and Margarita,
living with Fabry disease.



FIRST FOR FABRY



“If you don't take care of the inside of you, it won't take care of you. You need to do what needs to get done.”

Treated patient, living with Fabry disease.

IMPORTANT SAFETY INFORMATION (CONT'D)

Fabrazyme can cause serious side effects, including:

Severe Allergic Reactions Including Anaphylaxis

Approximately 1% of patients who received Fabrazyme experienced a severe allergic or anaphylactic reaction during their infusion. Some of these reactions were life-threatening, and included:




- Swelling reactions included: swelling of the face, mouth and throat, narrowing of breathing airways, low blood pressure, hives, difficulty swallowing, rash, trouble breathing, flushing, chest discomfort, itching and nasal congestion.
- Tell your healthcare professional if you experience any of these symptoms.



WHY FABRAZYME? BECAUSE IT'S *First* FOR FABRY



FIRST FOR FABRY

	<p>FIRST Prescribed Treatment:</p> <ul style="list-style-type: none"> • #1 prescribed FDA-approved treatment for Fabry patients 2 years and up, regardless of genetic variant. Fabrazyme can be used for all genders or disease severity*
	<p>FIRST in Evidence:</p> <ul style="list-style-type: none"> • The safety of Fabrazyme has been assessed in 4 clinical trials involving 162 patients with over 473 patient-years of experience
	<p>FIRST for Patients:</p> <ul style="list-style-type: none"> • Acting first for the Fabry community with a 20+ year commitment to supporting patients at every step of their journey

OVER 800 FEMALES IN THE US ARE ON FABRAZYME TREATMENT*



*Data on file. Based on publicly available patient numbers as of December 2021.

■ SEE IF FABRAZYME IS RIGHT FOR YOU AT fabrazyme.com/about-fabrazyme.

IMPORTANT SAFETY INFORMATION (CONT'D)

Severe Allergic Reactions Including Anaphylaxis (cont'd)

- Your healthcare professional may give you medicines before you receive Fabrazyme to help manage these reactions.

In clinical studies, some patients developed IgE antibodies or a reaction to an allergy skin test specific to Fabrazyme. IgE antibodies can sometimes be produced by the body's immune system during an allergic reaction. Your healthcare professional may test you for IgE antibodies if you experience a suspected allergic reaction to help assess the risks and benefits of continuing treatment.



THE SAFETY PROFILE OF FABRAZYME® HAS BEEN *well established*



FIRST FOR FABRY

THE SAFETY OF FABRAZYME HAS BEEN ASSESSED IN 4 CLINICAL TRIALS INVOLVING 162 PATIENTS WITH OVER 473 PATIENT-YEARS OF EXPERIENCE

In clinical trials, common side effects that occurred in 20% or more of people treated with Fabrazyme, and in more than 2.5% of people who received placebo (control group), include:

Side effect	Fabrazyme (n=80)	Placebo (n=60)
Upper respiratory tract infection	53%	42%
Chills	49%	13%
Fever (pyrexia)	39%	22%
Headache	39%	28%
Cough	33%	25%
Burning and/or tingling sensation in hands and feet (paresthesia)	31%	18%
Fatigue	24%	17%
Swelling in the limbs (peripheral edema)	21%	7%
Dizziness	21%	8%
Rash	20%	10%

n=number of patients.

Talk to your doctor about any side effects you experience when taking Fabrazyme. Read below for more information about what to expect from your infusions.

INDICATION AND USAGE

Fabrazyme® is used to treat adults and children 2 years of age and older with confirmed Fabry disease.

IMPORTANT SAFETY INFORMATION

WARNING: SEVERE ALLERGIC REACTIONS

Patients treated with enzyme replacement therapies have experienced allergic reactions, including severe or life-threatening reactions (known as anaphylaxis). Anaphylaxis has occurred during the early course and after repeated treatment with enzyme replacement therapy.

Your healthcare professional should initiate Fabrazyme in a healthcare setting with appropriate medical monitoring and support measures. If a severe allergic or anaphylactic reaction occurs, your healthcare professional will immediately stop the infusion and provide appropriate medical treatment. Seek immediate medical care should symptoms occur.



IMPORTANT SAFETY INFORMATION (CONT'D)

Fabrazyme can cause serious side effects, including: Severe Allergic Reactions Including Anaphylaxis

Approximately 1% of patients who received Fabrazyme experienced a severe allergic or anaphylactic reaction during their infusion. Some of these reactions were life-threatening, and included:

- Swelling of the face, mouth and throat, narrowing of breathing airways, low blood pressure, hives, difficulty swallowing, rash, trouble breathing, flushing, chest discomfort, itching and nasal congestion.
- Tell your healthcare professional if you experience any of these symptoms.
- Your healthcare professional may give you medicines before you receive Fabrazyme to help manage these reactions.

Infusion-Associated Reactions

In clinical studies, 59% of patients experienced infusion-associated reactions (IARs) during Fabrazyme administration, some of which were severe. IARs are defined as those occurring on the same day as your infusion. IARs occurred more frequently in patients who were positive for anti-Fabrazyme antibodies than those who did not have anti-Fabrazyme antibodies.

- You may receive medicines to help prevent IARs. IARs have happened in some patients even after taking these medications before their infusions.




Fabrazyme[®]
agalsidase beta

FIRST FOR FABRY

Ammeris,
living with Fabry disease.



IMPORTANT SAFETY INFORMATION (CONT'D)

Infusion-Associated Reactions (cont'd)

- If an IAR occurs, tell your healthcare professional, who may slow the infusion rate, stop the infusion, and/or provide appropriate medical treatment as needed.
- People with advanced Fabry disease may have heart problems, which could put them at a higher risk for severe complications from IARs. Tell the healthcare professional for your infusions if you have known heart problems.

Common Side Effects

Side effects reported in 20% or more of Fabrazyme treated patients in clinical studies compared to placebo were upper respiratory tract infection, chills, fever, headache, cough, burning and/or tingling sensation, fatigue, swelling in the legs, dizziness, and rash.



Fabrazyme[®]
agalsidase beta

FIRST FOR FABRY



Jenna,
living with Fabry disease.



START TREATING YOUR FABRY DISEASE NOW AND

YOU WILL THANK *You*

Dear Blanca,

You were 28 and your daughter was almost 5 when you were both diagnosed with Fabry. It was not easy. You both had to make space in your daily life for these new treatments – you at diagnosis, her at age 14. You got a lot of pushback about starting a child at such a young age. But you knew her health came first. It took a few years to get Sophia on treatment, but nothing could stop you. You advocated for yourself and your daughter. You chose what worked for you and FOUND YOUR PEOPLE! You were convinced women were not just carriers. You trusted your intuition because no one knows your body like you do.

The best gift you give your daughter is taking care of yourself. You must be strong for one another. Always be grateful for the decisions you made on this journey with your daughter.

Forever,
Blanca

Individual results may vary.


Fabrazyme[®]
agalsidase beta

FIRST FOR FABRY

IMPORTANT SAFETY INFORMATION (CONT'D)

Infusion-Associated Reactions

In clinical studies, 59% of patients experienced infusion-associated reactions (IARs) during Fabrazyme administration, some of which were severe. IARs are defined as those occurring on the same day as your infusion. IARs occurred more frequently in patients who were positive for anti-Fabrazyme antibodies than those who did not have anti-Fabrazyme antibodies.

- You may receive medicines to help prevent IARs. IARs have happened in some patients even after taking these medications before their infusions.



CareConnect Personalized Support Services IS HERE TO *support* YOUR JOURNEY



FIRST FOR FABRY

Sanofi acts first for patients. CareConnect offers personalized support services, representing our more than 35-year commitment to supporting patients' individual needs in the rare disease community.

OUR RANGE OF SUPPORT TO HELP PATIENTS LIVING WITH A RARE DISEASE INCLUDES:



Disease-specific information, including genetic education



Care coordination for treatment



Dedicated CareConnect Patient Education Liaisons and Case Managers



CONTACT A CASE MANAGER
1-800-745-4447, OPTION 3



CONNECT WITH US ONLINE
WWW.CARECONNECTPSS.COM



THERE ARE A NUMBER OF ORGANIZATIONS DEDICATED TO PROVIDING INFORMATION AND SUPPORT TO PEOPLE LIVING WITH FABRY DISEASE AND OTHER GENETIC CONDITIONS. [Find support resources here >](#)

IMPORTANT SAFETY INFORMATION (CONT'D)

Infusion-Associated Reactions (cont'd)

- If an IAR occurs, tell your healthcare professional, who may slow the infusion rate, stop the infusion, and/or provide appropriate medical treatment as needed.
- People with advanced Fabry disease may have heart problems, which could put them at a higher risk for severe complications from IARs. Tell the healthcare professional for your infusions if you have known heart problems.



ACT NOW AND You WILL THANK You

- You are not just a “carrier.” Fabry disease is progressive and can impact your organs
- Affected females may experience a wide range of symptoms, and some can be life altering
- Guidelines recommend ERT like Fabrazyme at early signs of disease in females



FABRAZYME IS FIRST FOR FABRY

- **#1 prescribed FDA-approved treatment** for Fabry patients 2 years and up, regardless of genetic variant*
- **1st in Evidence** with over 473 patient-years of experience and 4 clinical trials
- **1st for the Fabry Community** with a 20+ year commitment to supporting patients at every step of their journey

ORGAN DAMAGE FROM FABRY CAN PROGRESS “SILENTLY” EVEN IF YOU DON’T FEEL SICK.

PUT YOUR ORGAN HEALTH FIRST AND ASK YOUR DOCTOR ABOUT FABRAZYME TODAY.

Learn more at fabrazyme.com/about-fabrazyme.

*Data on file. Based on publicly available patient numbers as of December 2021.

Sanofi does not provide medical advice, diagnosis, or treatment. The health information contained herein is provided for general educational purposes only. Your healthcare professional is the best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.



450 Water Street, Cambridge, MA 02141. ©2024 Sanofi. All rights reserved. Fabrazyme and Sanofi are registered trademarks of Sanofi or an affiliate. CareConnect Personalized Support Services is a trademark of Sanofi or an affiliate. MAT-US-2208302-v2.0-08/2024.

Tonia and Katie,
living with Fabry disease.



FIRST FOR FABRY



“ You are getting treated for yourself. But there are so many others around you that are affected by this disease. They’ll thank you also because you can’t take care of them if you’re falling apart.”

Treated patient, living with Fabry disease.